Pharmacodynamic Evaluation of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
Phase of Trial: Phase IV
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Clopidogrel (Primary) ; Ticagrelor
- Indications Coronary artery disease
- Focus Pharmacodynamics
- Acronyms SWAP-4
- 15 Mar 2018 Status changed from active, no longer recruiting to completed.
- 11 Mar 2018 Primary endpoint (Platelet reactivity Unit-superiority of C-600 mg-24h versus C-75 mg-24h after switching from ticagrelor on PRU levels) has not been met, according to results published in the Circulation Journal.
- 11 Mar 2018 Results published in the Circulation Journal.